3D Printing in Personalized Drug Delivery

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Pharmaceutical Technology, Manufacturing and Devices".

Deadline for manuscript submissions: 20 September 2025 | Viewed by 514

Special Issue Editors


E-Mail Website
Guest Editor
SRI International, Menlo Park, CA 94025, USA
Interests: amorphous solid dispersions; 3D printing; personalized dosage forms; controlled drug release; sustained-release dosage forms; floating dosage forms; gastro-retentive dosage forms; hot melt extrusion; spray drying; solubility enhancement

grade E-Mail Website
Guest Editor
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK
Interests: 3D printing; polymorphism; thermal analysis; isothermal calorimetry; differential scanning calorimetry

Special Issue Information

Dear Colleagues,

Pharmaceutics is pleased to announce a Special Issue on "3D Printing in Personalized Drug Delivery". The emergence of 3D printing technology has revolutionized drug formulation and delivery, enabling the production of highly customized dosage forms tailored to individual patient needs, strengthening precision medicine. This innovative approach offers unparalleled flexibility in controlling drug release profiles, combining multiple drugs in a single dosage form, and optimizing drug delivery for specific populations, such as pediatrics, geriatrics, and patients with rare metabolic disorders. Recent advances in 3D printing techniques, including fused deposition modeling, inkjet printing, and stereolithography, have facilitated the creation of complex and functional drug delivery systems. This Special Issue aims to highlight the latest developments in 3D-printed pharmaceuticals, focusing on formulation strategies, manufacturing challenges, regulatory considerations, and clinical applications. Contributions addressing topics such as personalized medicine, patient-centric drug design, and scalability are particularly welcome.

We invite researchers, clinicians, and industry experts to share their findings and insights, advancing the application of 3D printing technologies in creating personalized and patient-specific drug delivery solutions. In this Special Issue, original research articles and reviews are welcome. We look forward to receiving your contributions.

Dr. Nagi Reddy Dumpa
Prof. Dr. Simon Gaisford
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • 3D printing
  • personalized medicine
  • precision medicine
  • on-demand manufacturing
  • drug delivery systems
  • patient-centric formulations
  • additive manufacturing
  • controlled release
  • gastro-retentive and floating dosage forms
  • multi-drug delivery
  • regulatory challenges in 3D printing manufacturing

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

26 pages, 3061 KiB  
Article
Three-Dimensional-Printed Isoniazid Chewable Gels for On-Demand Latent Tuberculosis Treatment in Children
by Amanda de O. E. Moreira, Lêda Maria S. Azevedo Neta, Márcia Pietroluongo, Ana Paula dos S. Matos, Beatriz B. Correa, Beatriz H. Ortiz, André da S. Guimarães, Marcio Nele, Carollyne M. Santos, Ana Elizabeth C. Fai, Maria Helena Gonçalves, Flávio M. Shimizu, Monique S. Dos Santos, Rosemberg B. Moure, Diogo D. Nascimento, André Luis de A. Guimarães, Saint Clair dos S. G. Junior, Alessandra L. Vicosa and Lucio M. Cabral
Pharmaceutics 2025, 17(5), 658; https://doi.org/10.3390/pharmaceutics17050658 - 17 May 2025
Viewed by 371
Abstract
Background/Objectives: Pediatric drug administration is hindered by difficulties in swallowing conventional medications and the unpalatable taste of many drugs. Among diseases highlighting the need for improved pediatric delivery, tuberculosis (TB) stands out. One form of the disease is latent TB infection (LTBI), [...] Read more.
Background/Objectives: Pediatric drug administration is hindered by difficulties in swallowing conventional medications and the unpalatable taste of many drugs. Among diseases highlighting the need for improved pediatric delivery, tuberculosis (TB) stands out. One form of the disease is latent TB infection (LTBI), which is concerning in children. Effective LTBI treatment is crucial for prevention, with isoniazid (INH) widely used for its proven efficacy and safety. This study aims to develop innovative 3D-printed chewable gels containing INH for LTBI treatment. Methods: The gels were formulated using gelatin and carrageenan gum, sugar-free sweeteners, and flavoring. Two batches were prepared, and using 3D printing (3DP) with a semi-solid extrusion (SSE) module, chewable gels were produced. Rheological properties were measured to assess the feasibility of 3DP-SSE, evaluating the structural integrity and adequate fluidity of the formulation. The 3D-printed chewable gels were evaluated by visual, mass, and dimensional characteristics. In addition, the water activity, texture profile, INH and degradation product content, in vitro release, and taste-masking were investigated. Results: The optimized formulation maintained suitable rheological properties for 3DP-SSE, demonstrating consistent weight, dimensions, and stability after the process. The texture achieved a balance between printing parameters and shape maintenance, and the INH presented an immediate-release profile (>85% within 30 min). The chewable gels showed an improvement in palatability compared to conventional INH tablets. Conclusions: This innovative approach offers a promising solution for pediatric LTBI treatment, as it improves efficacy, medication acceptability, and on-demand access. Full article
(This article belongs to the Special Issue 3D Printing in Personalized Drug Delivery)
Show Figures

Graphical abstract

Back to TopTop